Australia’s Therapeutic Goods Administration (Australia MRA) has postponed until the end of June 2024, the implementation of the agreed acceptable levels of nitrosamine impurities (NTTPs; 37 ng per day) for Sitagliptin, a diabetes medicine.
They “determined that an intake level of NTTP of up to 246 ng per day until 30 June 2024 does not pose an increased health concern based on short-term exposure compared with the risks for patients that cannot access their sitagliptin medicines.”
https://www.tga.gov.au/news/safety-alerts/sitagliptin-diabetes-medicines-safety-advisory